The MAP Group Unites Three Companies Under One New Brand Name, KINTIGA™

Cambridge, UK, 27 January 2025 – The MAP Group, a pan-European specialist pharmaceutical and biotechnology strategic consultancy focused on driving therapies through the complex medical, regulatory and market access landscape to maximise success in Europe, today announced that they will be rebranding as Kintiga, confirming its commitment to bring unity to the three companies making up the Group, MAP Patient Access, AxTalis, and SKC consulting.       

The new name signals the company’s evolution to one aligned organisation, with shared and synergistic capabilities focused on partnering with health technology developers to elevate client capabilities and expand European patient access. Kintiga empowers their clients to achieve their goals by providing comprehensive strategic guidance, unparalleled innovative solutions, and local expertise throughout the complex regulatory and payer journey.

The name, Kintiga, fuses “kin” (kindred) with the dynamic energy of “kinetic” and the specialised expertise of “tigris” (tiger), embodying the collaborative power and uniqueness of the three companies united. Kintiga reflects a consultancy with a shared purpose and unique approach, delivering high-impact solutions with agility and focus.

Steve Glass, the Group CEO, commented, “The new name, Kintiga, along with the bold new campaign, reflect our renewed vision and align us  under one combined brand.  While we will have a new name, we continue to offer our clients unparalleled support throughout the complex journey to achieve successful patient access across Europe, with our tailored approach, global perspective, and local expertise. We look forward to embracing new opportunities together as Kintiga.”

In 2024, The MAP Group, now Kintiga, acquired SKC Beratungsgesellschaft mbH, a strategic consultancy based in Hannover, Germany, the leading German market access and pricing and reimbursement consultancy, supporting pharma, biotech, medtech and digital health companies with complex strategic issues. Also in 2024, the MAP Group acquired the Belgium based consultancy, AxTalis, which broadened the Group’s capabilities, including regulatory strategy and compliance and medical affairs, in addition to strong market access capabilities in the Benelux region that complement well established existing offerings.

Kintiga has established operations across the UK, Ireland, Benelux, and Germany, with extensive experience across more than 200 clients in 20 markets. 

About Kintiga

Kintiga is Europe’s largest independent specialist pharmaceutical and biotechnology management consultancy. Its unique capabilities enable companies to maximise the value of their product portfolios, while providing patients with life-changing health solutions, by facilitating access to medicines across Europe’s complex medical, regulatory and payer environment. Kintiga provides a unique combination of specialist consultancy products and services across the development path to commercialisation, along with an online membership platform providing uninterrupted access to experts as well as an extensive and unique database, set of tools and invaluable content, to a wide range of pharmaceutical and biotech companies across Europe. Kintiga is headquartered in the United Kingdom, with additional sites across Europe, providing its range of products and services to customers across the globe, and backed by Kester Capital.

For more information about Kintiga, visit www.kintiga.com